Healthcare Services industry stocks trade higher on the bourses

Ipca Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524494 | NSE: IPCALAB

23 Mar 2020 Evaluate

Healthcare Services industry stocks were trading higher after the government approved Rs 13,760 crore package to boost production of bulk drugs, medical devices.

Ipca Laboratories is currently trading at Rs 1407.95, up by 36.10 points or 2.63% from its previous closing of Rs. 1371.85 on the BSE. The scrip opened at Rs. 1485.00 and has touched a high and low of Rs. 1615.70 and Rs. 1269.90 respectively. So far 38757 shares were traded on the counter.

Thyrocare Technologies is currently trading at Rs 530.00, up by 24.25 points or 4.79% from its previous closing of Rs 505.75 on the BSE. The scrip opened at Rs 519.90 and has touched a high and low of Rs. 574.00 and Rs 490.00 respectively. So far 25277 shares were traded on the counter.

Minister of State for Chemicals and Fertilisers Mansukh Mandaviya has said that the government has approved four schemes with an incentive outlay of Rs 9,940 crore and Rs 3,820 crore for bulk drugs and medical devices respectively, to boost their domestic production in the country and exports. He said the Cabinet also approved a sum of Rs 3,000 crore for the next five years for the scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks.

Mandaviya also stated that a sum of Rs 6,940 crore has been approved for the Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country. He said the PLI scheme will lead to expected incremental sales of Rs 46,400 crore and significant additional employment generation over eight years. He added that the scheme for promotion of medical device parks seeks to promote medical device parks in the country in partnership with the states.

The minister further said that a maximum grant-in-aid of Rs 100 crore per park will be provided to the states. It will have financial implications of Rs 400 crore. He noted that the PLI scheme for promoting domestic manufacturing of medical devices with financial implications of Rs 3,420 crore and the expenditure to be incurred for the schemes on promotion of medical devices will be for the next five years.

Ipca Laboratories Share Price

1569.70 6.00 (0.38%)

07-May-2026 12:43 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1842.80
Dr. Reddys Lab	1309.95
Cipla	1374.15
Zydus Lifesciences	941.40
Lupin	2469.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.